“Psychedelic Science Funders Collaborative
PSFC is a community of philanthropists dedicated to supporting psychedelic medicine and science. Our world today is experiencing epidemic levels of mental illness. Existing psychiatric treatments fail to address the suffering of the hundreds of millions of people worldwide affected by conditions such as PTSD, depression, and addiction. Emerging research indicates that psychedelic medicine has the potential to be a breakthrough in treating these and other conditions.
The Psychedelic Science Funders Collaborative (PSFC), a 501(c)(3) nonprofit, supports research on and clinical trials of physician-prescribed psychedelic medicines and patient access to these treatments. PSFC was born in 2017 out of a realization that psychedelic medicine has the potential to make an enormous impact and has an achievable path to regulatory approval, but has been systemically underfunded.
MDMA-assisted psychotherapy has received Breakthrough Therapy designation from the FDA, and in November 2018, historic Phase 3 trials of MDMA began. If successful, these trials could result in the first-ever regulatory approval of a Schedule I psychedelic compound as soon as 2021. Psilocybin trials have also made remarkable progress toward FDA approval, with ongoing Phase 2 trials and Breakthrough Therapy designation.
PSFC operates as a flexible network coordinated by a low-overhead organization to:
Identify and evaluate high-impact funding opportunities in psychedelic medicine
Provide advisory support to scientists and organizations in the psychedelic field, including expertise in pharmaceutical development, organizational growth, and public communications
Serve as a resource for philanthropists who have specific interests in psychedelics and are interested in advice and collaboration to amplify the collective impact
Foster community among philanthropists, scientists, and the tireless professionals dedicated to the clinical approval of psychedelics
Learn more about the potential impacts of these treatments, and get more details on our funding priorities .”